Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Amortization of Deferred Charges: 2019-2023

Historic Amortization of Deferred Charges for Harmony Biosciences Holdings (HRMY) over the last 3 years, with Jun 2023 value amounting to $424,000.

  • Harmony Biosciences Holdings' Amortization of Deferred Charges rose 3.16% to $424,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $1.7 million, marking a year-over-year decrease of 1.18%. This contributed to the annual value of $1.7 million for FY2022, which is 25.69% down from last year.
  • Harmony Biosciences Holdings' Amortization of Deferred Charges amounted to $424,000 in Q2 2023, which was up 1.92% from $416,000 recorded in Q1 2023.
  • In the past 5 years, Harmony Biosciences Holdings' Amortization of Deferred Charges registered a high of $1.4 million during Q4 2020, and its lowest value of $340,000 during Q1 2020.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $420,000 (2021), whereas its average is $474,100.
  • Examining YoY changes over the last 5 years, Harmony Biosciences Holdings' Amortization of Deferred Charges showed a top increase of 105.00% in 2021 and a maximum decrease of 69.97% in 2021.
  • Harmony Biosciences Holdings' Amortization of Deferred Charges (Quarterly) stood at $1.0 million in 2019, then soared by 33.21% to $1.4 million in 2020, then crashed by 69.97% to $418,000 in 2021, then climbed by 0.96% to $422,000 in 2022, then climbed by 3.16% to $424,000 in 2023.
  • Its last three reported values are $424,000 in Q2 2023, $416,000 for Q1 2023, and $422,000 during Q4 2022.